CJC-1295 Teichman SL et al
Retatrutide is distinguished by its triple agonist activity across GLP-1, GIP, and glucagon receptors, allowing researchers to investigate multiple metabolic pathways within a single experimental framework
They represent thousands of people dealing with a problem that goes far beyond simple discomfort
Lifestyle modifications are the foundation of any weight loss effort, and even small changes can be helpful over the long run
Recalls & Warnings April 25, 2024 Yogi Tea Recalled Due to Pesticides On April 19, 2024, Yogi Tea issued a recall of over 54,800 packs of Yogi Echinacea Immune Support tea after a sample of echinacea tested above acceptable limits for multiple pesticides

Gastrointestinal Very common (10% or more): Gastrointestinal adverse reactions (up to 73%), nausea (up to 44%), vomiting (up to 36%), diarrhea (up to 30%), constipation (up to 24.2%), abdominal pain (up to 20%) Common (1% to 10%): Dyspepsia, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, viral gastroenteritis, increased amylase, increased lipase, dry mouth, severe gastrointestinal adverse reactions, delayed gastric emptying Uncommon (0.1% to 1%): Acute pancreatitis, appendicitis Frequency not reported : Hemorrhoids, hiccups Postmarketing reports : Ileus, intestinal obstruction, severe constipation, hiccups, acute pancreatitis, necrotizing pancreatitis In clinical trials in adults using the subcutaneous injection for weight reduction, 73% of treated patients reported gastrointestinal adverse reactions, including severe reactions (4.1%)